Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...

Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

A panelist discusses how given PODIUM-303's benefits across all subgroups, the primary patient population that should receive chemotherapy alone rather than the combination with retifanlimab would be ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus ...

This new article publication from Acta Pharmaceutica Sinica B, discusses targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by ...

Discover new treatments like ART-123 advancing toward approval to prevent long-term nerve damage caused by ...